Abbvie Inc ABBV

$262.82 +2.89 (1.11%)

Valuation

Market cap
459,242,496,000
Revenue TTM
$61,160,000,000
Net income TTM
$4,226,000,000
PE ratio
24.07
Forward PE
18.62
Profit margin
6.91%
Debt to equity
-12.03

Trading

Volume
5,863,000
Avg volume
4,647,482
Day's range
$257.87 – $264.06
Shares out
1,766,793,000
Stochastic %K
43%
Beta
0.24
Analysts
Strong Sell
Price target
$278.20

Price

Company profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to...

Show more

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Industry
Drug Manufacturers - General
Sector
Healthcare
Phone
847 932 7900
Website
https://www.abbvie.com
Address
1 North Waukegan Road, North Chicago, United States

Latest news

Stocktwits

55X_ROI_Q1_2026 Oct 2, 11:42 PM
$SLS $MRNA $XBI $ABBV - protip: While we are seeing this miraculous survival everyone should know its Gps - • - Preventing Relapse and extending survival, doing what its done in all 7 Prior Trials Including in 2 Phase 2 Trials for AML Remission Maintenance. • GPs Stat Sig Phase 2 in CR2 was 21 months, in an older(74) all MRD+ trial w much Less dosing. • GPs Phase 2 MOS for CR1/ First Remission was not reached > 67.6 months - BAT /Onureg MOS in the quazar trial is just 24.7 Months. And the VIALE-M Phase 3 Trial Failed - Adding Venetoclax to Onureg FAILED for First Remission Patients. Its not complicated.
0 replies
55X_ROI_Q1_2026 Oct 2, 8:41 PM
$ABBV $MRNA $SLS $XBI Not Sure who needs to See this from the Old YG19/ Short SLS REDDIT Page -- all the Fake Long Short Lowlife there going on and on about Transplants .... - its a SHORT CANARD Do Some RESEARCH / From the Onureg/CC486 Phase 3 Trial in First Remission // Ineligible for Transplant -- Just 6.7% ended up Getting Transplant Just 6.7% ended up Getting Transplant - in First Remission Just 6.7% ended up Getting Transplant - It'll be Less in CR2/3 Just 6.7% ended up Getting Transplant - a NOTHING BURGER Just 6.7% ended up Getting Transplant - SHORT SCUMBAGS Lie FACTS don't/
0 replies
55X_ROI_Q1_2026 Oct 2, 7:43 PM
$SLS $MRNA $XBI $ABBV 144 Days since the 78th Event - from the 60th to 78th - we'd been seeing about 1 Event Per month - it has been 144 Days waiting for 2 . . . 79th likely already occurred ... SLS Share Price will at Least 10x the moment the Imminent Gps Phase 3 Results are Announced. - at least 10x to a $120 Share Price / $24B Mcap and will continue climbing - Will Be ANY Day. - Gps will Generate Peak Revenue north of $10B just for AML Remission Maintenance. - Gps Phase 2 MOS for CR1 was not reached > 67.6 months / SOC is 24.7 - GPs Phase 2 MOS for CR2 was stat sig 21 months - in an older all MRD+ setting ... • GPS Phase 3 MOS for CR2 Patients will come in > 34 months. • Onureg / BAT for CR1 Patients is only 24.7 ... Hello, Hello???? $MRNA added $50B in Market Value in the days After its Cancer vaccine P3 results were announced ... SLS will be Doing something Similar.
0 replies
LiveFree0rDie Oct 2, 6:37 PM
$ABBV $MRNA $SLS $XBI “Imminent” is a relative term. 😂 Happy Friday yall!
0 replies
55X_ROI_Q1_2026 Oct 2, 6:16 PM
$SLS SLS Share Price will at Least 10x the moment the Imminent Gps Phase 3 Results are Announced. - at least 10x to a $120 Share Price / $24B Mcap and will continue climbing - Will Be ANY Day. - Gps will Generate Peak Revenue north of $10B just for AML Remission Maintenance. $MRNA added $50B to its Mcap in the days after it announced its P3 Cancer vaccine results -- same thing will be happening here. $XBI $ABBV
0 replies
SparkyReturns Oct 2, 2:38 PM
$MRNA Biotech investors, have a breaking investment idea. ICU I can't believe the broader market is sleeping on this. Saves half of the people who would otherwise die from sepsis due to cytokine storm. Billions in TAM, about to roll out not just for kids but soon for adults in 2027 and no one realizes the import. 6 Breakthrough Device Designations ranging from Kidney, to Cardio, to Respiratory. Unreal we got in on the ground floor. $TAK $ABBV $BAYRY $PFE
0 replies
UltraInstinct Oct 2, 2:13 PM
$ABBV Sleeping giant!!!
0 replies
Hawksssss Oct 2, 3:57 AM
$ABBV $KURA $SNDX This is a hematologist prescriber survey embedded within the recent SNDX note, focused on NPM1 mutant AML (the largest subset of adult AML, ~30% of all AML). Core survey findings 1. Diagnosis & testing behavior Virtually all responding leukemia specialists now routinely test newly diagnosed AML patients for NPM1 mutation at baseline. Previously, many viewed revumenib only as a KMT2Ar drug; survey shows this perception has shifted after NPM1 label approval + real-world data. 2. Treatment preference for R/R NPM1 AML (already approved setting) ◦ Efficacy / deep MRD response is the #1 decision factor (ranked far above safety, oral convenience, or price). ◦ HCPs say revumenib’s ability to drive MRD negativity is its biggest differentiator vs older salvage regimens. ◦ Survey uptake expectation: Respondents expect Revuforj to capture a dominant share of eligible R/R NPM1 patients, even with competing menin inhibitor now on market.
2 replies